Malignant Exocrine Pancreas Neoplasm — Trials

Malignant Exocrine Pancreas Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

930 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 360
Recruiting: 209
Ph III recruiting: 23
Growth YoY: +39.4%
Industry share: 40%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (136)

clinicaltrialsPublishedShowing 1–50 of 112 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06390059	EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma	completed	Phase 2	84	NovoCure Ltd.INDUSTRY	4	Sep 4, 2026	clinicaltrials
NCT04493060	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	completed	Phase 2	22	Mayo ClinicOTHER	1	Sep 3, 2026	clinicaltrials